Sign In
Buy SXTP
$1.45
-0.0200 (-1.36%)
At Close: Jun 03, 2026
60 Degrees Pharmaceuticals Inc. Announces ARAKODA® Promotional Pilot in Advance of Expanded U.S. Launch
09:02am, Thursday, 03'rd Oct 2024
Highlights include increased ARAKODA® (tafenoquine) brand awareness and utilization through virtual sales outreach using digital behavioral analytics and a co-pay program to assist consumers with out
60 Degrees Pharmaceuticals, Inc. Announces $4 Million Private Placement Priced At-the-Market Under Nasdaq Rules
08:00am, Wednesday, 04'th Sep 2024
60 Degrees Pharmaceuticals raises $4M through private placement for working capital, commercialization, and R&D, with H.C. Wainwright as placement agent.
60 Degrees Pharmaceuticals, Inc. Regains Compliance with Nasdaq Listing Requirements
02:48pm, Wednesday, 28'th Aug 2024
WASHINGTON, Aug. 28, 2024 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (“60P” or the “Company”), a pharmaceutical company focused on developing new medicines fo
60 Degrees Pharmaceuticals Inc. (SXTP) Reports Q2 Loss, Tops Revenue Estimates
02:01pm, Wednesday, 14'th Aug 2024
60 Degrees Pharmaceuticals Inc. (SXTP) came out with a quarterly loss of $4.23 per share versus the Zacks Consensus Estimate of a loss of $3.96. This compares to loss of $16.81 per share a year ago.
60 Degrees Pharmaceuticals Announces Second Quarter 2024 Results
11:01am, Wednesday, 14'th Aug 2024
Q2 2024 net product revenues doubled year-over-year to $125 thousand Sequential (quarter-over-quarter) net product revenue growth of 18.3% Gross profit increased from ($124 thousand) to $35 thousand,
Why Is 60 Degrees Pharmaceuticals (SXTP) Stock Up 29% Today?
01:52pm, Monday, 12'th Aug 2024
60 Degrees Pharmaceuticals (NASDAQ: SXTP ) stock is gaining on Monday after the specialty pharmaceutical company announced an agreement with the University of Kentucky. This agreement will have the Un
60 Degrees Pharma Provides University of Kentucky with Right of Reference to ARAKODA® NDA in Support of SJ733 Phase IIb Study
09:12am, Monday, 12'th Aug 2024
60 Degrees Pharma grants U of Kentucky a right of reference to ARAKODA® NDA for a Phase IIb trial combining SJ733 with tafenoquine to treat vivax malaria.
60 Degrees Pharmaceuticals, Inc. Announces 1:12 Reverse Stock Split
09:26am, Tuesday, 06'th Aug 2024
60 Degrees Pharma (NASDAQ: SXTP) announces a 1-for-12 reverse stock split, effective August 12, 2024 to meet Nasdaq's $1.00 minimum bid price requirement.
60 Degrees Pharmaceuticals Awarded Contract with U.S. Army for ARAKODA® Supply Chain Upgrade Support
09:02am, Thursday, 25'th Jul 2024
60 Degrees Pharmaceuticals secures a U.S. Army contract to support ARAKODA® packaging validation, with Q1 2024 sales up 515% year-over-year to $105.7K.
60 Degrees Pharmaceuticals Signs Clinical Trial Agreements With All Planned Trial Sites for Tafenoquine Babesiosis Study
08:29am, Friday, 19'th Jul 2024
60 Degrees Pharma begins enrolling patients for a tafenoquine babesiosis trial at Yale, Tufts, and Rhode Island Hospital, with results expected Sept., 2025
Why Is 60 Degrees (SXTP) Stock Up 56% Today?
07:58am, Friday, 19'th Jul 2024
60 Degrees (NASDAQ: SXTP ) stock is on the rise Friday alongside heavy early morning trading of the specialty pharmaceutical company's shares. This has more than 12.5 million shares of SXTP stock bei
WASHINGTON, July 09, 2024 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (“60 Degrees Pharmaceuticals” or the “Company”), a pharmaceutical company focused on develo
60 Degrees Pharmaceuticals enrolls first patient in a clinical study at Tufts to assess safety and efficacy of tafenoquine in treating acute babesiosis.
60 Degrees Pharmaceuticals has entered an agreement with Tufts Medical Center to conduct a clinical trial that will evaluate the safety and efficacy of tafenoquine for the treatment of babesiosis in h
60 Degrees Pharmaceuticals funds a study at NC State to test for Babesia spp in chronic fatigue patients, aiming to link these infections to CFS symptoms.
